Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of<sup>177</sup>Lu-PSMA I&T-Reference-Cited by-同舟云学术

Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of¹⁷⁷Lu-PSMA I&T

Published:2023-09-07 Issue:11 Volume:64 Page:1765-1771
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Karimzadeh Amir,Soeiro Paula,Feuerecker Benedikt,Hecker Charlotte-Sophie,Knorr Karina,Heck Matthias M.,Tauber Robert,D’Alessandria Calogero,Weber Wolfgang A.,Eiber Matthias,Rauscher Isabel

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference19 articles.

1. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis

2. Treatment experiences, information needs, pain and quality of life in men with metastatic castrate-resistant prostate cancer: results from the EXTREQOL study;Jenkins;Clin Oncol (R Coll Radiol).,2019

3. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

4. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

5. 177LuLu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial;Hofman;Lancet.,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on: “Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta‑analysis”;Targeted Oncology;2024-07-19

2. Organ and tumor dosimetry including method simplification for [177Lu]Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer;EJNMMI Physics;2024-07-17